Corcept Therapeutics Incorporated (NASDAQ:CORT) said that the primary endpoint was met in the treatment phase of CATALYST, a ...

Over a decade into selling Korlym to treat endogenous hypercortisolism, also known as Cushing syndrome, Corcept Therapeutics ...

Corcept Therapeutics drug Korlym, which treats hypercortisolism and difficult-to-control type 2 diabetes, met its primary endpoint in the treatment phase of CATALYST, a randomized, double-blind, ...

Korlym recorded sales of $346.9 million in the first nine months of 2023. The judgment passed by the district judge is likely to open doors for early generic competition.

Shares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months against the industry’s decline ...

Corcept Therapeutics specializes in cortisol-modulating drugs, with Korlym targeting Cushing Syndrome and a promising pipeline, including Relacorilant, for diabetes and ovarian cancer. CORT's ...

虽然CATALYST的完整结果计划在明年的医学会议上公布，但目前的发现表明，Korlym可能是治疗高皮质醇血症和难以控制的糖尿病患者的一个有价值的选择。该公司的强劲表现反映在其过去一年115.73%的回报率上，分析师对未来盈利保持积极预测。这一消息基于Corcept ...

Corcept Therapeutics (CORT) announced that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym in patients with ...

The study found that the drug Korlym significantly improved blood sugar levels in affected patients. According to InvestingPro analysis, the company appears to be trading above its Fair Value, though ...

Korlym showed a 1.47% reduction in hemoglobin A1c in patients with hypercortisolism and type 2 diabetes, surpassing placebo's 0.15%. CATALYST Phase 4 study screened 1,057 patients, confirming ...

The company’s sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing a strong demand in the past ...